摘要
背景:肝细胞癌(HCC)是最致命的肝癌。慢性肝炎和随后的肝纤维化和肝硬化是导致肝癌的主要原因。HBV感染不仅导致肝癌,而且导致肝外恶性肿瘤。但是目前对于HBV感染者进行肝细胞癌筛查的重要性及其途径、肝癌的危险因素、导致肝细胞癌的可能机制以及HBV相关肝细胞癌的潜在治疗方法的研究较少。 方法:综述现有研究HBV相关性HCC的筛查、危险性、新的生物标志物、机制及治疗。 结果:血清甲胎蛋白(AFP)应用于慢性乙型肝炎患者的HCC筛查。HBV高载量与肝癌风险增加有关。HBV基因型和基因多态性有助于增加HCC的风险。ku86,ku86抗体,miR-18a,miR-122、miR-150可能是乙肝病毒相关性肝细胞癌的可靠指标。Micro RNAs与HBx在HBV相关的HCC中发挥关键作用。两种类型的药物,传统的干扰素(IFN),核苷类似物(NAS),最近已成为治疗慢性乙型肝炎感染有效的药物,但是这些患者的治疗方案尚未建立。 结论:全面了解HBV感染如何引起肝细胞癌的发生,对于开发更有效的抗病毒治疗和预防肝硬化和肝癌转为晚期有着重要意义。定期筛查HBV感染者是减少这些患者HCC发病率的一个切实有效的方法,应加大力度探索更可靠的HCC早期检测标志物,结合干扰素和NAS及其他治疗方法来更好的预防肝癌复发。
关键词: 乙型肝炎病毒,感染,肝癌,肝纤维化,癌,血清AFP
图形摘要
Current Cancer Drug Targets
Title:Hepatitis B Virus (HBV) Infection and Hepatocellular Carcinoma- New Insights for an Old Topic
Volume: 17 Issue: 6
关键词: 乙型肝炎病毒,感染,肝癌,肝纤维化,癌,血清AFP
摘要: Background: Hepatocellular carcinoma (HCC) is the most deadly form of liver cancer. Chronic hepatitis and subsequent liver fibrosis and cirrhosis are the major causes of HCC. HBV infection results not only in HCC but also extra-hepatic cancers. However, the importance and approaches for HCC screening in HBV infected individuals, the risk factors of HCC, the possible mechanisms leading to HCC and the potential therapeutic approaches of HBV-related HCC have less been systematic reviewed.
Methods: In this study, we reviewed the screening, risk, new biomarker, mechanism and therapeutic of HBV-related HCC. Results: Serum AFP should be used for the HCC screening in CHB patients. Higher HBV viral load is associated with increased risk of HCC. HBV genotype and genetic polymorphism contribute to the risk of HCC.Ku86, Ku86 antibody, miR-18a, miR-122 and miR-150 may be reliable markers of HBVrelated HCC. MicroRNAs and HBx play a key role in HBV-related HCC. Two types of drugs, conventional interferon (IFN), and nucleoside analogs (NAs), have recently become available for the treatment of CHB infection. However, treatment guidelines for these patients have not yet established. Conclusion: A comprehensive understanding of how HBV infection causes HCC is of great importance in developing more effective antiviral therapy and prevention of late stage consequences such as cirrhosis and HCC. Regular screening in HBV infected individuals is a practically useful approach in reducing the HCC incidence in these patients. More reliable markers for HCC early detection should be explored. Combining IFNs and NAs with other curative approaches have superior benefits in preventing HCC recurrence.Export Options
About this article
Cite this article as:
Hepatitis B Virus (HBV) Infection and Hepatocellular Carcinoma- New Insights for an Old Topic, Current Cancer Drug Targets 2017; 17 (6) . https://dx.doi.org/10.2174/1568009616666160926124530
DOI https://dx.doi.org/10.2174/1568009616666160926124530 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of MicroRNA in the Diagnosis and Therapy of Hepatocellular Carcinoma: A New Frontier
MicroRNA Ponatinib: A Review of Efficacy and Safety
Current Cancer Drug Targets Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Sources of β-Cells for Cell Therapy in Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Viral Product Trafficking to Mitochondria, Mechanisms and Roles in Pathogenesis
Infectious Disorders - Drug Targets Anti-Cancer Efficacy of Intravenously Administered Tumor- Targeted Vesicles Entrapping Tocotrienol
Pharmaceutical Nanotechnology Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Novel Conjugated Quinazolinone-Based Hydroxamic Acids: Design, Synthesis and Biological Evaluation
Medicinal Chemistry In Vivo Treatment Efficacy of Essential Oil Isolated from Seeds of <i>Momordica charantia</i> in Streptozotocin-Induced Diabetes Mellitus
Recent Patents on Biotechnology Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets A Role for Milk Proteins and their Peptides in Cancer Prevention
Current Pharmaceutical Design Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery Fungal Mediated Generation of Mammalian Metabolites of Fenofibrate and Enhanced Pharmacological Activity of the Main Metabolite Fenofibric Acid
Drug Metabolism Letters Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry MicroRNAs as Cancer Biomarkers
MicroRNA MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy Editorial [Hot Topic: Oncohematology: From Bench to Bedside (Guest Editor: Vincenzo De Feo)]
Mini-Reviews in Medicinal Chemistry